Accessible text: pCPA Temporary Access Process (pTAP) flowchart

Accessible text for the pCPA Temporary Access Process (pTAP) flowchart

Version Date: February 19, 2025

  1. Initial economic and clinical reports received from Canada's Drug Agency
  2. pCPA performs evaluation resulting in decision to engage or not to engage in pTAP negotiation
    • If no, pTAP process ends. Drug will not be considered for public coverage at this time
    • If yes, continue
  3. Structured pTAP negotiation process is initiated
    • If negotiation is unsuccessful, pTAP process ends. Drug will not be considered for public coverage at this time
    • If negotiation is successful, continue
  4. Temporary public drug plan price established. Temporary agreement established (eligible patients will receive temporary coverage once listed by individual public drug plans) The temporary agreement will be in effect until a final (long-term) agreement is negotiated, as triggered by a positive final health technology assessment (HTA)  recommendation.
  5. Confirmatory evidence submitted for health technology assessment (HTA) within pCPA time frame
    • If not confirmed, pTAP process ends. Manufacturers assume coverage of existing patients
    • If confirmed, continue
  6. Final HTA recommendation received from Canada's Drug Agency
    • if negative, pTAP process ends. Manufacturers assume coverage of existing patients
    • if positive, pCPA will negotiate for a final (long-term) agreement. The drug will no longer be part of the pTAP process